Many patients with hypertension require combination therapy to reduce their blood pressure to target levels. Treatment with an angiotensin-converting enzyme (ACE) inhibitor such as perindopril, plus a diuretic such as indapamide, is frequently used to control hypertension. Coversyl Plus combines perindopril, 4 mg, and indapamide, 1.25 mg, in a single tablet, taken once daily, and thus can simplify treatment schedules and increase patient compliance. Coversyl Plus can reduce blood pressure to a greater extent than monotherapy with some other antihypertensive agents, and to an equivalent extent to certain other combination regimens. Results from a recent, large-scale clinical outcomes study have also shown that Coversyl Plus reduces the risk of premature death, micro- and macrovascular outcomes, and renal outcomes (such as the development of microalbuminuria) in hypertensive patients with type 2 diabetes. Importantly, these benefits appear to be independent of a range of treatments and the presence or absence of hypertension at baseline. Coversyl Plus is associated with an excellent safety and tolerability profile, and thus remains a valuable treatment option for hypertension. In addition, Coversyl Plus has been shown to be of particular benefit in significantly reducing risk in hypertensive patients with type 2 diabetes.
|Original language||English (US)|
|Number of pages||14|
|Journal||Drugs in Context|
|State||Published - 2008|
- Coversyl Plus